PROBLEM TO BE SOLVED: To provide an antibody interacting with interleukin-1 receptor type 1 (IL-1R1), a method for treating IL-1-mediated diseases by administering the antibody, and a method for detecting the amount of IL-1R1 in a sample by using the antibody.ブライアン バーナム...
Therapeutic protein fusions comprising anti-HER2 antibody and MicB sequences are described along with methods for their production and use
In vitro analyses have shown anti-HIV immunotoxins to be among the most effective AIDS antivirals tested. Because HIV has been continually selected by antibody, immunotoxins targeted to constant domains of viral antigens may not elicit drug-resistant mutants. A clinical trial with CD4-PE40, a ...
3.2. Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs 3.2. Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in...
Brain inflammation is a major factor in epilepsy, and the high mobility group box-1 (HMGB1) protein is known to contribute significantly to the generation of seizures. Here, we investigated the therapeutic potential of an anti-HMGB1 monoclonal antibody (mAb) in epilepsy. anti-HMGB1 mAb attenuated...
3.2. Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in four dogs 3.2. Therapeutic anti-IgE monoclonal antibody single chain variable fragment (scFv) safety and immunomodulatory effects after one time injection in...
Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE antib...
Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. A novel , , is described that exhibits a central role in in vitro and in vivo. Modulation of -mediated signals with specific anti-antibodies in vitro effic... Naln Utku,T Heinemann,SG...
13. The method of claim 12, wherein the portion of the antibody comprises a Fab, or a single chain antibody. 14. The method of claim 5, wherein the protein comprises soluble extracellular region of CD40 ligand, or variants thereof including conservative substituents, or portion thereof; or...
We report the development and characterization of r84, a fully human monoclonal antibody that binds human and mouse VEGF and selectively blocks VEGF from interacting with VEGFR2 but does not interfere with VEGF∶VEGFR1 interaction. Selective blockade of VEGF binding to VEGFR2 by r84 is shown ...